INGREDIENTS

Each 0.6 mL of drops contains: Active: simethicone, 40 mg. Inactive: carboxymethylcellulose sodium, citric acid, manitol microcrystalline cellulose, natural flavor, purified water, Red 22, Red 28, sodium benzoate, sodium citrate, xanthan gum, non-staining formula contains no Red 22 or Red 20.

INDICATIONS

For relief of the symptoms of excess gas in the digestive tract. Such gas is frequently caused by excessive swallowing of air or by eating foods that disagree. The defoaming action of INFANTS' MYLICON® Drops relieves flatulence by dispersing and preventing the formation of mucus-surrounded gas pockets in the gastrointestinal tract. INFANTS' MYLICON® Drops act in the stomach and intestines to change the surface tension of gas bubbles enabling them to coalesce, thereby freeing and eliminating the gas more easily by belching or passing flatus.

DIRECTIONS

Infants (under 2 years): 0.3 ml four times daily after meals and at bedtime, or as directed by a physician. The dosage can also be mixed with 1 oz of cool water, infant formula or other suitable liquids to ease administration.

Adults and children: 0.6 ml four times daily, after meals and at bedtime, or as directed by a physician.

WARNINGS

Do not exceed 12 doses per day except under the advice and supervision of a physician. Keep this and all drugs out of the reach of children.

HOW SUPPLIED

INFANTS' MYLICON® Drops are available in bottles of 15 ml (0.5 fl oz) and 30 ml (1.0 fl oz) original pink, pleasant tasting liquid and non-staining formula. NDC 16837-630; 16837-911.

PRODUCT PHOTO(S):

NOTE: These photos can be used only for identification by shape, color, and imprint. They do not depict actual or relative size.

The product samples shown here have been supplied by the manufacturer and reproduced in full color by PDR as a quick-reference identification aid. While every effort has been made to assure accurate reproduction, please remember that any visual identification should be considered preliminary. In cases of poisoning or suspected overdosage, the drug' identity should be verified by chemical analysis.

images/pills/p01318e2.jpg



Copyright© 2001 Medical Economics